Thank you to all of the witnesses for your testimony, and particularly you, Ms. Goulding, for having your personal experience and your advocacy, despite your own challenges. It's fascinating and so important to hear your testimony, but I'm going to give you a break.
Dr. Arts, you talked about the advantage that we have, with so many people infected, as a kind of potential for cohorts. But I'm going to pivot to Dr. Falcone for now and ask if it is also a disadvantage that COVID is now becoming so common? I think I know more people who have had COVID than have not. Maybe I'm mixing in the wrong crowds. Personally, I've been spared so far, but is long COVID clinically distinct enough that we will still be able to recognize it given the increasing prevalence of people who have had COVID, or will we really be dependent on that search for biomarkers?